LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Erweiterte Suche

Ihre letzten Suchen

  1. AU="Catharine Sturgeon"
  2. AU=Bhardwaj Neeru
  3. AU=Hamdani Muhammad Afzal
  4. AU="Wen, O"
  5. AU="de Oliveira, Luciana Maia Nogueira"
  6. AU="Sanabria, Mauricio"
  7. AU="Tronnier, Michael"
  8. AU="Yu, Yaonan"
  9. AU="Gradl, W"
  10. AU="Grossklags, Jens"
  11. AU="Andreas M. Köster"
  12. AU="Diana Karolina Maniak"
  13. AU="Cahuana-Hurtado, Lucero"
  14. AU="Ebert, Christoph"
  15. AU="Köhler, Matthias"
  16. AU=Fitzgerald Amelia Lucy AU=Fitzgerald Amelia Lucy
  17. AU="Yang, Charles"
  18. AU="Fraser, Alice j"
  19. AU=MacKenzie James A
  20. AU=Guettari Moez AU=Guettari Moez
  21. AU=McLeod Carolyn
  22. AU="Patel P.M"
  23. AU="Patel N.M"
  24. AU="Naganawa, Mika"
  25. AU="Viecelli, Claudio"
  26. AU=Valls Joan
  27. AU="Yang, Qizhang"
  28. AU=Wilt Timothy J
  29. AU="Dene R. Littler" AU="Dene R. Littler"
  30. AU="Petrenko, Andrei"
  31. AU=Valentino Kristin
  32. AU=Swash M
  33. AU="Adedipe, Ifeoluwa"
  34. AU=Shen Hongcheng
  35. AU="Padhy, Biswajit"
  36. AU="Kruglikov, Alibek"
  37. AU="Tasu, Jean Pierre"
  38. AU="Floate, Kevin D"
  39. AU="Mark Rijpkema"
  40. AU="Gjeloshi, Klodian"
  41. AU="Lucie Beaudoin"

Suchergebnis

Treffer 1 - 2 von insgesamt 2

Suchoptionen

  1. Artikel ; Online: Alpha-Fetoprotein Detection of Hepatocellular Carcinoma Leads to a Standardized Analysis of Dynamic AFP to Improve Screening Based Detection.

    Thomas G Bird / Polyxeni Dimitropoulou / Rebecca M Turner / Sara J Jenks / Pearce Cusack / Shiying Hey / Andrew Blunsum / Sarah Kelly / Catharine Sturgeon / Peter C Hayes / Sheila M Bird

    PLoS ONE, Vol 11, Iss 6, p e

    2016  Band 0156801

    Abstract: Detection of hepatocellular carcinoma (HCC) through screening can improve outcomes. However, HCC surveillance remains costly, cumbersome and suboptimal. We tested whether and how serum Alpha-Fetoprotein (AFP) should be used in HCC surveillance. Record ... ...

    Abstract Detection of hepatocellular carcinoma (HCC) through screening can improve outcomes. However, HCC surveillance remains costly, cumbersome and suboptimal. We tested whether and how serum Alpha-Fetoprotein (AFP) should be used in HCC surveillance. Record linkage, dedicated pathways for management and AFP data-storage identified i) consecutive highly characterised cases of HCC diagnosed in 2009-14 and ii) a cohort of ongoing HCC-free patients undergoing regular HCC surveillance from 2009. These two well-defined Scottish patient cohorts enabled us to test the utility of AFP surveillance. Of 304 cases of HCC diagnosed over 6 years, 42% (129) were identified by a dedicated HCC surveillance programme. Of these 129, 47% (61) had a detectable lesion first identified by screening ultrasound (US) but 38% (49) were prompted by elevated AFP. Despite pre-HCC diagnosis AFP >20kU/L being associated with poor outcome, 'AFP-detected' tumours were offered potentially curative management as frequently as 'US-detected' HCCs; and had comparable survival. Linearity of serial log10-transformed AFPs in HCC cases and in the screening 'HCC-free' cohort (n = 1509) provided indicators of high-risk AFP behaviour in HCC cases. An algorithm was devised in static mode, then tested dynamically. A case/control series in hepatitis C related disease demonstrated highly significant detection (p<1.72*10-5) of patients at high risk of developing HCC. These data support the use of AFP in HCC surveillance. We show proof-of-principle that an automated and further refine-able algorithmic interpretation of AFP can identify patients at higher risk of HCC. This approach could provide a cost-effective, user-friendly and much needed addition to US surveillance.
    Schlagwörter Medicine ; R ; Science ; Q
    Thema/Rubrik (Code) 610
    Sprache Englisch
    Erscheinungsdatum 2016-01-01T00:00:00Z
    Verlag Public Library of Science (PLoS)
    Dokumenttyp Artikel ; Online
    Datenquelle BASE - Bielefeld Academic Search Engine (Lebenswissenschaftliche Auswahl)

    Zusatzmaterialien

    Kategorien

  2. Artikel ; Online: Methods for the evaluation of biomarkers in patients with kidney and liver diseases

    Peter J Selby / Rosamonde E Banks / Walter Gregory / Jenny Hewison / William Rosenberg / Douglas G Altman / Jonathan J Deeks / Christopher McCabe / Julie Parkes / Catharine Sturgeon / Douglas Thompson / Maureen Twiddy / Janine Bestall / Joan Bedlington / Tilly Hale / Jacqueline Dinnes / Marc Jones / Andrew Lewington / Michael P Messenger /
    Vicky Napp / Alice Sitch / Sudeep Tanwar / Naveen S Vasudev / Paul Baxter / Sue Bell / David A Cairns / Nicola Calder / Neil Corrigan / Francesco Del Galdo / Peter Heudtlass / Nick Hornigold / Claire Hulme / Michelle Hutchinson / Carys Lippiatt / Tobias Livingstone / Roberta Longo / Matthew Potton / Stephanie Roberts / Sheryl Sim / Sebastian Trainor / Matthew Welberry Smith / James Neuberger / Douglas Thorburn / Paul Richardson / John Christie / Neil Sheerin / William McKane / Paul Gibbs / Anusha Edwards / Naeem Soomro

    Programme Grants for Applied Research, Vol 6, Iss

    multicentre research programme including ELUCIDATE RCT

    2018  Band 3

    Abstract: Background: Protein biomarkers with associations with the activity and outcomes of diseases are being identified by modern proteomic technologies. They may be simple, accessible, cheap and safe tests that can inform diagnosis, prognosis, treatment ... ...

    Abstract Background: Protein biomarkers with associations with the activity and outcomes of diseases are being identified by modern proteomic technologies. They may be simple, accessible, cheap and safe tests that can inform diagnosis, prognosis, treatment selection, monitoring of disease activity and therapy and may substitute for complex, invasive and expensive tests. However, their potential is not yet being realised. Design and methods: The study consisted of three workstreams to create a framework for research: workstream 1, methodology – to define current practice and explore methodology innovations for biomarkers for monitoring disease; workstream 2, clinical translation – to create a framework of research practice, high-quality samples and related clinical data to evaluate the validity and clinical utility of protein biomarkers; and workstream 3, the ELF to Uncover Cirrhosis as an Indication for Diagnosis and Action for Treatable Event (ELUCIDATE) randomised controlled trial (RCT) – an exemplar RCT of an established test, the ADVIA Centaur® Enhanced Liver Fibrosis (ELF) test (Siemens Healthcare Diagnostics Ltd, Camberley, UK) [consisting of a panel of three markers – (1) serum hyaluronic acid, (2) amino-terminal propeptide of type III procollagen and (3) tissue inhibitor of metalloproteinase 1], for liver cirrhosis to determine its impact on diagnostic timing and the management of cirrhosis and the process of care and improving outcomes. Results: The methodology workstream evaluated the quality of recommendations for using prostate-specific antigen to monitor patients, systematically reviewed RCTs of monitoring strategies and reviewed the monitoring biomarker literature and how monitoring can have an impact on outcomes. Simulation studies were conducted to evaluate monitoring and improve the merits of health care. The monitoring biomarker literature is modest and robust conclusions are infrequent. We recommend improvements in research practice. Patients strongly endorsed the need for robust and conclusive ...
    Schlagwörter biomarkers ; liver disease ; kidney disease ; prostate-specific antigen ; monitoring trials ; simulation of biomarker studies ; elf test ; elucidate ; renal cancer ; renal transplantation ; diagnosis of cirrhosis ; Public aspects of medicine ; RA1-1270
    Thema/Rubrik (Code) 610
    Sprache Englisch
    Erscheinungsdatum 2018-06-01T00:00:00Z
    Verlag NIHR Journals Library
    Dokumenttyp Artikel ; Online
    Datenquelle BASE - Bielefeld Academic Search Engine (Lebenswissenschaftliche Auswahl)

    Zusatzmaterialien

    Kategorien

Zum Seitenanfang